This is a working overview of fatty acid oxidation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description for typical solid reference material. |
| Solubility | Poorly soluble in water; soluble in DMSO | Solubility depends on solvent, purity, and form. |
| Storage | Cool, dry, protected from light | Long-term storage often uses low temperature and desiccant. |
| Common analytical method | LC-MS/MS | Used for detection and quantification in biological matrices. |
| Common synonyms | GW-501516; GW501516; endurobol | Naming varies among literature, vendors, and databases. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
I agreed emphatically with Henry Stimson. Once we had got ourselves into the business of bombing cities, we might as well do the job competently and get it over with. I felt better that morning than I had felt for years... Those fellows who had built the atomic bombs obviously knew their stuff... Later, much later, I would remember [the downside]. I am convinced that to avoid nuclear war it is not sufficient to be afraid of it. It is necessary to be afraid, but it is equally necessary to understand. And the first step in understanding is to recognize that the problem of nuclear war is basically not technical but human and historical. If we are to avoid destruction we must first of all understand the human and historical context out of which destruction arises. In 1967, in his capacity as a military adviser, Dyson wrote an influential paper on the issue of possible US use of tactical nuclear weapons in the Vietnam War. When a general said in a meeting, "I think it might be a good idea to throw in a nuke now and then, just to keep the other side guessing..." Dyson became alarmed and obtained permission to write a report on the pros and cons of using such weapons from a purely military point of view. (This report, Tactical Nuclear Weapons in Southeast Asia, published by the Institute for Defense Analyses, was obtained, with some redactions, by the Nautilus Institute for Security and Sustainability under the Freedom of Information act in 2002.) It was sufficiently objective that both sides of the debate based their arguments on it.
== Mechanism of action == Two main ideas about how it might work have been proposed over the years. The first idea, which has been proven wrong, is that insulin makes cells more permeable, so that the chemotherapy drugs are absorbed faster into cells. The other idea is that insulin might cause the cells to start dividing, which makes them more susceptible to destruction of many cytotoxic chemotherapy drugs.
=== TrkB === The TrkB receptor is encoded by the NTRK2 gene and is member of a receptor family of tyrosine kinases that includes TrkA and TrkC. TrkB autophosphorylation is dependent upon its ligand-specific association with BDNF, a widely expressed activity-dependent neurotrophic factor that regulates plasticity and is dysregulated following hypoxic injury. The activation of the BDNF-TrkB pathway is important in the development of short-term memory and the growth of neurons.
Sources: en.wikipedia.org
==== Crf-dynorphin-kor cascade ==== Diverse stressors initiate CRF release which subsequently leads to dynorphin release and KOR activation in limbic circuits. This integrated stress response is mediated primarily by corticotropin-releasing factor (CRF), one of the main neuropeptide integrators of the stress response. Physical stressors trigger CRF release from the hypothalamic paraventricular nucleus (PVN). Cold exposure provokes CRF secretion from the hypothalamus and produces increases in plasma glucocorticoids. Acute physical stressors such as forced swimming, inescapable footshock, and restraint stress similarly lead to CRF release. Acute stress induces rapid increases in plasma corticosterone levels that are dependent on CRF secretion. Intravenous CRF administration induces rapid increases in KOR phosphorylation in striatal, VTA, amygdaloid, hippocampal, and nucleus accumbens (NAcc) components of stress and anxiety circuits. These CRF-induced increases are absent in prodynorphin (PDYN) knockout mice. Social defeat stress model activates CRF and dynorphin. Learned helplessness also engages these systems. Fear conditioning and fear-related stress produce KOR-dependent behavioral responses through CRF receptor. The uncontrollability and inescapability of the stressor substantially augments the response. Even brief, non-intensive stressors produce significant neurobiological and behavioral effects when unpredictable and uncontrollable, whereas identical stressors with controllability demonstrate attenuated activation of stress systems.
=== Pharmacodynamics === DPIA is a norepinephrine transporter inhibitor with an IC₅₀ value of 3.1 µM, as well as a dopamine transporter inhibitor with a potency approximately 13 times weaker than that of amphetamine, but 7 times more potent than amphetamine in inhibiting the serotonin transporter, although, unlike amphetamine, DPIA does not exhibit monoamine-releasing activity. It exhibits moderate affinity for 5-HT1A serotonin receptors (Ki = 3.5 µM) and for alpha-1A-adrenoreceptors (Ki = 0.12 µM), and binds to alpha-2A-adrenoreceptors and TAAR1. In experiments on rodents, DPIA produced the same central effects and toxicity as amphetamine, but was less potent. Interestingly, unlike amphetamine, DPIA caused a reduction in heart rate and blood pressure (exhibiting cardiodepressant properties).
November 3 COVID-19 pandemic: In Wisconsin, Green Bay Packers quarterback Aaron Rodgers tests positive for COVID-19 and will miss the team's matchup against the Kansas City Chiefs. Smartmatic announces that they have sued conservative news channels One America News Network and Newsmax for defamation and false claims about their voting machines during the 2020 election. November 4 An investigatory hearing is held by the State Bar of Texas to kick off a multi-start process that would decide the fate of attorney Sidney Powell, who spread conspiracy claims after the 2020 presidential election. The National Basketball Association announces that they have launched an investigation into Phoenix Suns owner Robert Sarver over allegations of sexism and racism. November 5 The U.S. House of Representatives votes 228–206 to pass the Infrastructure Investment and Jobs Act, a US$1.2 trillion infrastructure package. A crowd crush during a Travis Scott concert at the Astroworld Festival in Houston kills ten people and injures more than 300. November 7 – Alabama native Nimblewill Nomad becomes the oldest person to hike on the Appalachian Trail. November 8 On October 15, the White House announced that it would reopen international borders to non-essential travel from the EU, UK, China, India, South Africa, Iran and Brazil on November 8. The travel restrictions have been in place for 18 months, coming into effect in the early days of the pandemic.
Sources: en.wikipedia.org
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.
Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.
Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.